We investigated the incidence of duodenal gastric metaplasia and its response to Helicobacter pylori eradication in patients with duodenal ulcer or erosive duodenitis. Gastric and duodenal biopsies were taken from patients with endoscopically detected H. pylori positive duodenal ulcer or erosive duodenitis, and the presence and extent of duodenal gastric metaplasia was recorded. Patients were given omeprazole 20 mg twice daily for 2 weeks, and amoxicillin 1 g and clarithromycin 500 mg twice daily for 10 days, and then ranitidine for a further 8 weeks. Biopsies were repeated 6 months after the start of treatment. Duodenal gastric metaplasia was initially present in 22 patients (52%) and was more frequent in ulcer patients than in duodenitis patients, but not significantly so (69% versus 45%). After treatment, H. pylori was eradicated in 68% of duodenal gastric metaplasia patients and the duodenum was normal endoscopically in 85% of these patients. Duodenal gastric metaplasia was improved or eliminated in 12/15 H. pylori eradicators (80%) and in 517 H. pylori non-eradicators (71%), a non-significant difference. The improvement in duodenal gastric metaplasia appeared to be independent of H. pylori eradication.
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INTRODUCTION
Gastric type epithelium or gastric metaplasia in the duodenum is often found in patients with severe duodenitis and duodenal ulcer. It is generally believed to be a non-specific and reparative response of the duodenal mucosa to injurious agents. Previous studies have postulated that high gastric acid output is the major cause of gastric motaplasia;' -4 inhibiting or reducing gastric acidity was associated with significantly decreased duodenal gastric metaplasia in these reports. In more recent studies Helicobactet pylori has been implicated as the most important factor in the development of duodenal gastric metaplasia." -I; The regression of duodenal gastric metaplasia in duodenal ulcer patients after eradication of H. pylori has been suggested by these investigations, but this has not been confirmed by others." -H Thus, there are conflicting findings at present about the role of H. pylori in duodenal gastric metaplasia, and the importance of eradication therapy for the course of duodenal gastric metaplasia.
In the present study, we aimed to investigate the prevalence of duodenal gastric metaplasia in H. pylori positive duodenitis/duodenal ulcer patients and, secondly, the importance of H. pylori eradication on the regression of gastric metaplasia in these patients.
PATIENTS AND METHODS PATIENTS
A total of 94 dyspeptic patients underwent upper gastrointestinal endoscopy over a 10-month period, and 42 patients who had endoscopically detected H. pylori positive duodenal ulcer or severe erosive duodenitis were enrolled into the study. Informed consent was obtained from each patient.
Patients were excluded from the study if they had received non-steroidal antiinflammatory drugs, antibiotics, or protonpump inhibitors within the preceding 4 weeks, if they were pregnant, had had previous gastric surgery, or were suspected of non-compliance.
PROCEDURES
Helicobacter pylori status was determined both histologically (two antral and two corpus biopsies) and by rapid urease test. During the endoscopy procedure, at least three biopsies from different parts of the duodenal bulb (anterior, superior and inferior wall) were taken. All specimens were immediately fixed in formalin and processed for histological examination. Biopsy sections were stained with haematoxylin and eosin for examination of histological inflammation, Toluidine blue for H. pylori detection, and Alcian blue/periodic acid-Schiff for the identification of gastric metaplasia (Fig. 1 ). The degree of duodenitis and gastritis was graded as none, mild, moderate or severe. The extent of the gastric-type epithelium on the duodenum was scored between 0 and 10 by examining the surface epithelium in 10 randomly selected areas using a magnification of 400X.
All of the patients were treated with omeprazole 20 mg twice daily for 2 weeks and amoxicillin 1 g plus clarithromycin 500 mg twice daily for 10 days. Gastric acid suppression using ranitidine 150 mg/day was continued for an additional 8 weeks.
Endoscopy and biopsies were repeated 6 months after the start of treatment. Eradication of H. pylori was assumed when both histological examination and the rapid urease test gave negative results. Patients in whom symptoms recurred during the study period were given only antacids. 
STATISTICAL ANALYSIS
The demographic and clinical features of the study groups were compared by the Wilcoxon rank sum test. Statistical analyses of the healing rates and eradication frequency between groups were made by the X 2 test with a Yates correction. A P-value < 0.05 was defined as statistically significant.
RESULTS
The endoscopic and histological findings before treatment are summarized in Table 1 .
Duodenal gastric metaplasia was detected in the biopsy samples of 22 patients (52%) at the first endoscopy; the characteristics and clinical findings of patients were similar when patients Helicobacter pylori eradication in duodenal gastric metaplasia were divided according to whether duodenal gastric metaplasia was present or absent ( Table 2) . Duodenal gastric metaplasia was present in 69% of ulcer patients (9/13) and 45% of duodenitis patients (13/29), a difference that was not statistically significant (P> 0.05). Helicobacter pylori eradication was achieved in 15 patients with duodenal gastric metaplasia (68%) but not in the remaining seven patients (31 %). The overall eradication rate was 76% in all patients (32/42). Recovery from duodenal gastric metaplasia was partially or completely achieved in 12 H. pylori eradicators (80%) and five non-eradicators (71.4%) after treatment (Figs 2 and 3) ; the rate of recovery from duodenal gastric metaplasia did not differ significantly between eradicators and non-eradicators (P > 0.05). The total rate of recovery from duodenal gastric metaplasia was 77% (17/22), a statistically significant improvement (P < 0.001). Duodenal inflammation also decreased considerably, both in patients in whom H. pylori was eradicated (27/32, 84%) and in those in which it was not eradicated (7/10, 70%); there was no statistically significant difference between eradicators and non-eradicators (P > 0.05). The endoscopy findings 6 months after the start of treatment are summarized in Table 3 .
DISCUSSION
Helicobacter pylori infection has recently been accepted as the most important factor in the pathogenesis of duodenal ulcer and its complications.v" The main mechanism for H. pylori associated duodenal ulcer is increased gastrin release stimulated by bacteria predominantly localized in the antrum. Increased gastric acid output accompanies gastrin secretion and results in excess duodenal acid load. Exposure to excessive acid causes the development of gastric type epithelium in the duodenal mucosa and allows colonization by H. pylori in the duodenum and subsequent inflammation, which may lead to ulceration of the mucosa.'! The development of gastric metaplasia in response to acid hypersecretion has been demonstrated in both experimental and human investigations." -4 Gastric metaplasia of the duodenum has also been found extensively in patients with Zollinger-Ellison syndrome." Reducing gastric acidity using acid-suppressing medications or surgical .,.
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• v: ....-. . • Section of duodenal biopsy in the same patient (as Fig. 1) showing significant healing of gastric metaplasia after treatment with omeprazo/e, amoxicillin, clarithromycin and ranitidine (Alcian blue/periodic acid-Schiff, x 100).
procedures has reduced the extent of gastric metaplasia in various studies.v'" The presence of gastric metaplasia has also been shown in non-ulcer dyspeptic patients or asymptomatic individuals with increased gastric acid output." These findings suggest that increased gastric acid output has a cardinal role in the formation of duodenal gastric metaplasia independent of H. pylori. It is not surprising, therefore. to detect duodenal gastric metaplasia in chronic antral H. pylori infection since the infection causes excess duodenal acid load. There is controversy as to whether H. pylori itself causes gastric metaplasia of the duodenum independently of acid output or whether it stimulates the further extension of previous metaplasia. Wyatt et a/. 15 found that gastric metaplasia of the duodenum was no more common in H. pylori positive patients, but if it was present it was more extensive in such patients. These findings suggest that mucosal injury of the 163 duodenum by H. pylori in these patients may further stimulate metaplasia. This may create a positive feedback for colonization by H. pylori and may result in increasing inflammation until mucosal integrity is impaired and ulceration occurs. Noach et al. 16 could not find a significant association between H. pylori infection and the presence and extent of duodenal gastric metaplasia. The mean extent of gastric metaplasia did not change significantly after H. pylorieradication and did not differ compared with patients with persisting infection. They 'concluded that unchanged gastric acid output after eradication of H. pylori was more important for the presence of gastric metaplasia than the H. pylori related inflammatory process. This suggestion is contrary to most studies in the medical literature, however. since eradication of H. pylori infection resulted in a fall in basal gastrin levels and basal acid output. Khulusi et a/. 4 showed that a reduction of approximately M Demiriz et al.
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After treatment
Effect oftreatment with omeprazole, amoxicillin, clarithromycin and ranitidine on duodenal gastric metaplasia in the patients in whom Helicobacter pylori was eradicated (n = 15) (a) and not eradicated (n = 7)(b). The score after treatment was recorded 6 months after the start of treatment Helicobacter pylori eradication in duodenal gastric metaplasia 40% in gastric metaplasia of the duodenum occurred both following H. pylori eradication and with gastric acid suppression alone. The combination of H. pylori eradication and acid suppression produced an additive effect with a 66% reduction in gastric metaplasia. These authors also found a positive relationship between the extent of gastric metaplasia and antral H. pylori density. So, gastric metaplasia was related partly to H. pylori and partly to gastric acidity. In another study, the same group has shown a Significant decline of gastric metaplasia in patients in whom H. pylori was eradicated compared with those in whom it was not eradicated, and suggested that H. pylori itself, at least in part, is responsible for producing gastric metaplasia of the duodenum."
In a more recent study, contrary to these findings, Kim et al? found no change in the extent of duodenal gastric metaplasia until 1 year after H. pylori eradication, in patients with duodenal ulcer, and concluded that the prevalence and the extent of gastric metaplasia were not related to H. pylori in patients with both duodenal ulcer and non-ulcer dyspepsia.
The study by Harris et al," confirmed these results and found no association between H. pylori and gastric metaplasia while high acid output was an important factor. The present study revealed that duodenal gastric metaplasia improved markedly in most of our patients after treatment of the duodenal ulcer or erosive duodenitis. This improvement was independent of H. pylori eradication and did not differ between eradicated and noneradicated groups. A strong acid suppressor agent, omeprazole, was used in our eradication regimen~in contrast to most studies, which have not used an acid suppressor in eradication schedules. As stated before, suppression of gastric acid output and healing of duodenal ulcers improves gastric metaplasia in the duodenum. Our results confirm this, and further suggest that eradication of H. pylori does not contribute to the regression of gastric metaplasia when gastric acid output is otherwise inhibited. The eradication of H. pylori without using an acid-suppressor may reduce gastric metaplasia as shown in some previous studies. Eradication of bacteria probably reduces gastric acid output compared with non-eradication in such situations but this effect may not be important when a strong acid suppressor drug is used. It seems that when omeprazol is used in the eradication regimen, gastric metaplasia of duodenum regresses markedly independently of H. pylori eradication.
Our findings confirm the view that gastric acid output has a major effect on the development of gastric metaplasia of the duodenum since suppression of acid is closely related to recovery from gastric metaplasia. In addition, H. pylori may have some effect on the development and extent of gastric metaplasia as a result of increased acid output. The effect of H. pylori on gastric acid secretion does not seem significant, however, in cases where gastric acid output has already increased. Whether the cessation of acid suppression causes recurrence of gastric metaplasia in such patients, especially in non-eradicators, is a matter for speculation at present. Long-term follow-up of these patients could answer this question and may assist a clearer understanding of the role of H. pylori.
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